SEGRAM aims to offer an alternative to glucocorticoid‑based treatment
Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy
SEGRAM aims to offer an alternative to glucocorticoid‑based treatment
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.